Aveo
Aug 01, 2011 at 16:46 | Source: PTI
Jun 14, 2011 at 16:57 | Source: PTI
Jan 02, 2009 at 16:11
Dec 02, 2008 at 17:56
Nov 07, 2008 at 13:34
.jpg)
_logo.jpg){kind=logo}
News across the web »
May 04, 2012 at 18:00 | Source: Bloomberg
May 03, 2012 at 04:32 | Source: Forbes
May 02, 2012 at 07:42 | Source: Economic Times
May 01, 2012 at 17:26 | Source: The Hindu BusinessLine
May 01, 2012 at 17:26 | Source: Business Today
Interact & exchange stock tips & market info »
Related News »
AVEO Pharmaceuticals, Inc. ( AVEO) recently initiated a phase I study with its oncology candidate, AV-203. AV-203 is an ERBB3 inhibitory antibody and AVEO's third clinical stage candidate. The multi-center, dose escalation study will evaluate the candidate ...
May 24, 2012 at 22:38 | Source: NASDAQ
AVEO Oncology (NASDAQ:AVEO - News) and Astellas Pharma Inc. (TSE:4503) today announced that detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1 st line Advanced RCC), will be presented on June 2 in an oral session by the principal ...
May 26, 2012 at 17:00 | Source: Yahoo Finance
Aveo Oncology (Nasdaq: AVEO) said it put its third molecule in the clinic today by starting a Phase 1 trial of its AV-203 drug candidate along with exploratory biomarkers in patients with advanced solid tumors. The Cambridge-based company said ...
May 20, 2012 at 23:55 | Source: Mass High Tech
(Reuters) - Patients taking a kidney cancer drug being developed by Aveo Pharmaceuticals Inc were half as likely to need a break from the medication due to side effects than those on the widely used medicine Nexavar, according to data released ...
May 16, 2012 at 21:58 | Source: msnbc.com
How many people can you fit into a car? It's a question that's been asked about any number of small cars. They're usually Volkswagen models, and those determined to find the answer are most likely to be a group of relatively small and flexible ...
May 19, 2012 at 06:24 | Source: Autoblog
Aveo Oncology is entering a competitive world for the treatment of kidney cancer, and it made a bold bet that its drug would prevail in the first head-to-head comparison of its kind against an active drug. Now the company is preparing to enter ...
May 16, 2012 at 21:58 | Source: Xconomy
Drugs, devices, and nonprofits showed up in this week’s New England life sciences news. —Promedior, a maker of treatments for tissue damage known as fibrosis, is moving its headquarters from Pennsylvania to Boston and has hired Suzanne ...
May 18, 2012 at 03:55 | Source: Xconomy
Aveo Oncology and partner Astellas Pharma Europe reported positive data from the pivotal Phase III study Viro-1, comparing the once-daily oral tyrosine kinase inhibitor candidate tivozanib with sorafenib in 517 patients with advanced renal cell ...
May 17, 2012 at 12:02 | Source: Genetic Engineering News
AVEO Oncology (Nasdaq:AVEO - News) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors. AV-203 is a monoclonal ...
May 26, 2012 at 11:09 | Source: Yahoo Finance